LDX Discussion, page-1259

- Circa $600,000-$1Million in product revenue (another 200%+ increase QoQ possible?)

@danhoff was correct. $600,000. Good to see and increase, but not unexpected given the lower PCP.

- Circa $4Million+ in services revenue. This would be $1.5Million Hologic, $900K BARDA receipts, $250K Burnet Revenue, plus other existing deals ( circa $1.6Million) So a total of roughly $4.3Million?

So including the $1Million from Hologic already on hand, services was $1.4Million. That includes BARDA funds. I would have a guess and say $250,000 was Burnet (the estimated revenues LDX indicated divided by the number of quarters estimated), so $750K is from other services we deal with.

- Burnet update with revenues reflected in the services side

Per AT1 Quarterly, 20,000 pascal units (in turn, 20,000 tests for LDX) will be manufactured for the upcoming US trial.

- Update on Hologic payments and status of this deal

That's a poor outcome. All of a sudden an "unexpected" delay occurred to alter the "recognised revenue". In turn, extending when the remainder $4Million to be received. I expect this will result in a poor market sentiment from this report.

- Update on the PHK study which has been going for some time in the US

All quiet on the western front.

- Update on Febridx study (number of patients tested, and or number of bacterial patients tested)

Bugger all sales and no change to what we already know.

- Clarity on other services deals progressing and whether there is any updates

Positive random comment about the defense thing: Also in January, the U.S. Defense Logistics Agency (DLA) awarded FebriDx a Distribution and Pricing
Agreement (DAPA) under the DLA Troop Support Medical Supply Chain Acquisition Program. This agreement authorizes FebriDx sales representatives to promote the product to the U.S. Military Services; however, it does not guarantee procurement.

Question is, WHY WASNT THIS ANNOUNCED PREVIOUSLY!?